Hansa Biopharma AB

Hansa Biopharma AB - PE Ratioverified

HNSBF

Price:

$3.7

Market Cap:

$3.77B

Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It is also developing HNSA-5487, a next generation IgG-cleaving enzyme to address acute and chronic neuro-autoimmune conditions, including myasthenia gravis. In addition, the company evaluates imlifidase in three therapy areas, including autoimmune, gene therap...[Read more]

Industry

Medical - Pharmaceuticals

IPO Date

2015-03-25

Stock Exchange

OTC

Ticker

HNSBF

The PE Ratio as of August 2026 (TTM) for Hansa Biopharma AB (HNSBF) is -4.47

According to Hansa Biopharma AB’s latest financial reports and current stock price. The company's current PE Ratio is -4.47. This represents a change of -3.49% compared to the average of -4.63 of the last 4 quarters.

Hansa Biopharma AB (HNSBF) Historical PE Ratio (quarterly & annually)

How has HNSBF PE Ratio performed in the past?

The mean historical PE Ratio of Hansa Biopharma AB over the last ten years is -18.37. The current -4.47 PE Ratio has changed 2.33% with respect to the historical average. Over the past ten years (40 quarters), HNSBF's PE Ratio was at its highest in in the September 2023 quarter at -1.80. The PE Ratio was at its lowest in in the September 2017 quarter at -50.71.

Quarterly (TTM)
Annual

Average

-18.37

Median

-8.26

Minimum

-50.18

Maximum

-1.66

Hansa Biopharma AB (HNSBF) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Hansa Biopharma AB PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 189.68%

Maximum Annual PE Ratio = -1.66

Minimum Annual Increase = -79.19%

Minimum Annual PE Ratio = -50.18

Quarterly (TTM)
Annual
YearPE RatioChange
2025-5.2271.04%
2024-3.0584.46%
2023-1.66-54.27%
2022-3.62-49.75%
2021-7.20-70.10%
2020-24.09158.55%
2019-9.32-79.19%
2018-44.76-10.80%
2017-50.1845.16%
2016-34.57189.68%

Hansa Biopharma AB (HNSBF) Average PE Ratio

How has HNSBF PE Ratio performed in the past?

The current PE Ratio of Hansa Biopharma AB (HNSBF) is less than than its 3-year, less than than its 5-year, and greater than its 10-year historical averages

3-year avg

-3.31

5-year avg

-4.15

10-year avg

-18.37

Hansa Biopharma AB (HNSBF) PE Ratio vs. Peers

How is HNSBF’s PE Ratio compared to its peers?

Hansa Biopharma AB’s PE Ratio is less than Silence Therapeutics plc (-2.66), less than Transgene S.A. (-2.72), less than Probi AB (publ) (235.14), less than Cellectis S.A. (-4.14), less than Santhera Pharmaceuticals Holding AG (-4.06), less than Immutep Ltd (-0.80), greater than Genfit S.a. (-7.98), less than Frontage Holdings Corporation (50.22), greater than hVIVO plc (-7.84), less than Mayne Pharma Group Limited (-2.90),

Build a custom stock screener for Hansa Biopharma AB (HNSBF) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Hansa Biopharma AB using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Hansa Biopharma AB (HNSBF) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Hansa Biopharma AB or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Hansa Biopharma AB's PE Ratio?

How is the PE Ratio calculated for Hansa Biopharma AB (HNSBF)?

What is the highest PE Ratio for Hansa Biopharma AB (HNSBF)?

What is the 3-year average PE Ratio for Hansa Biopharma AB (HNSBF)?

What is the 5-year average PE Ratio for Hansa Biopharma AB (HNSBF)?

How does the current PE Ratio for Hansa Biopharma AB (HNSBF) compare to its historical average?